Study of Iparomlimab and Tuvonralimab for resectable lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) before and after surgery for people with a certain type of lung cancer that can be removed. It aims to see if this treatment helps improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have non-small cell lung cancer (NSCLC) that has not been treated yet, stage II to IIIB (with lymph node involvement only in N2).
- Your tumor is considered removable by a team of doctors, including a lung cancer surgeon.
- You can provide a sample of your tumor tissue for testing.
- You have not had certain genetic mutations (EGFR or ALK) and have not received immunotherapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two immunotherapy drugs (which help your immune system fight cancer) with a type of precisely targeted radiation (SBRT) is safe and effective for people with early-stage non-small cell lung cancer. If you qualify, you might receive a treatment that could boost your body's ability to destroy cancer cells.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of two immunotherapy drugs plus chemotherapy to shrink lung tumors so they can be removed with surgery. The goal is to give patients with stage III unresectable non-small cell lung cancer a chance at surgery and a better outcome.
This trial tests two new immunotherapy drugs (QL1706 and QL1604) to see if they help keep limited-stage small cell lung cancer from coming back after you've finished chemo and radiation. The goal is to compare the two study drugs against each other to find a better way to extend your remission.
This trial tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with 2 or 4 cycles of chemotherapy before surgery can help shrink tumors and improve outcomes for people with early-stage (stage II-IIIB) non-small cell lung cancer. The goal is to make surgery more effective and possibly reduce the chance of cancer coming back.
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.